TGFB1 and neoplasm: Since TGFβ has pleiotropic activity on most cell types of the tumor and TGFβ blockade is not cytotoxic, it comes as no surprise that the mechanisms of action of anti-TGFβ therapy are as variable as the range of tumor types observed in the clinic.